Loading...
Market
Will Neuralink's Canadian trial show significant mobility improvement by 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Peer-reviewed publication or official Neuralink press release
Story
Neuralink Receives Health Canada Approval for First Clinical Trial in Canada for Quadriplegia Patients at Toronto Western Hospital
Nov 20, 2024, 08:02 PM
Neuralink has received approval from Health Canada to initiate its first clinical trial in Canada, specifically targeting individuals with quadriplegia due to amyotrophic lateral sclerosis (ALS) or spinal cord injury (SCI). Recruitment for the trial is now open, and eligible participants can register through the company's Patient Registry. The trial will take place at Toronto Western Hospital, marking it as the first non-U.S. site for Neuralink's brain implant testing. The initiative aims to explore the transformative potential of brain-computer interfaces (BCIs) for individuals with severe mobility impairments.
View original story
Similar markets
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Recruitment completion • 25%
Initial results published • 25%
Trial expansion approved • 25%
Trial discontinued • 25%
Regulatory issues • 25%
Technical failures • 25%
Patient recruitment difficulties • 25%
No major challenges • 25%